How India Exports Ezetimibe to the World

In the United States, Ezetimibe is approved under multiple Abbreviated New Drug Applications (ANDAs), as listed in the FDA's Orange Book. The presence of numerous ANDAs indicates a competitive generic market, facilitating broader access and affordability. The substantial export volume to the U.S. underscores the importance of Indian manufacturers in supplying Ezetimibe to this market. Notably, PIRAMAL PHARMA LIMITED alone contributed $315.6 million USD, representing 61.3% of India's total Ezetimibe exports, highlighting its pivotal role in the U.S. supply chain.

The FDA's regulatory framework for Ezetimibe involves rigorous evaluation of bioequivalence and manufacturing standards. Indian exporters must adhere to these stringent requirements to maintain market access. The high repeat buyer rate of 70.6% reflects sustained compliance and trust in the quality of Indian-produced Ezetimibe.

In the European Union, Ezetimibe is subject to marketing authorization by the European Medicines Agency (EMA). The significant export volumes to Germany (41.4%) and the Netherlands (4.0%) indicate robust demand within the EU. Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for Indian exporters to ensure product quality and safety.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and regulation of Ezetimibe. Post-Brexit, Indian exporters must navigate the UK's independent regulatory landscape, which may involve additional requirements distinct from the EU framework.

Ezetimibe is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025. This inclusion underscores its critical role in managing hypercholesterolemia globally. The WHO Model List serves as a guide for countries to develop their national essential medicines lists, promoting equitable access to vital medications. Additionally, Ezetimibe's specifications are detailed in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality benchmarks across different regions.

In India, Ezetimibe is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, Ezetimibe is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

The primary patent for Ezetimibe has expired, leading to the introduction of multiple generic versions in the market. This has intensified competition among manufacturers, contributing to reduced prices and increased accessibility for patients worldwide.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List, reaffirming Ezetimibe's inclusion due to its efficacy in managing cholesterol levels. This decision reflects the ongoing recognition of Ezetimibe's importance in global health.

In January 2026, the NPPA conducted a review of lipid-lowering agents' pricing in India. While Ezetimibe remained outside the DPCO, the review highlighted the need for monitoring price trends to ensure affordability without compromising quality.

In February 2026, the FDA issued updated guidance on bioequivalence studies for generic Ezetimibe formulations, emphasizing the need for robust clinical data to support ANDA approvals. This guidance aims to maintain high standards for generic medications entering the U.S. market.

In March 2026, the EMA released a report on the pharmacovigilance of lipid-lowering agents, including Ezetimibe, noting a favorable benefit-risk profile. The report encouraged continued monitoring to promptly identify and address any emerging safety concerns.

In March 2026, the WHO launched a global repository for National Essential Medicines Lists (nEMLs), providing a centralized platform for countries to share and access information on essential medicines, including Ezetimibe. This initiative aims to harmonize medicine selection and improve access worldwide.

These developments underscore the dynamic regulatory environment surrounding Ezetimibe, highlighting the importance of continuous compliance and vigilance by manufacturers and exporters.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). Approximately 41% of KSMs used in U.S.-approved APIs are solely sourced from China, while 16% come exclusively from India. This dependency poses a significant risk, as disruptions in China's supply chain can directly impact India's API production capabilities. For instance, environmental regulations in China have led to the shutdown of numerous chemical plants, causing supply shortages and price volatility in the global pharmaceutical market.

The Indian government has initiated measures to reduce this dependency. In October 2024, two greenfield plants were inaugurated under the Production Linked Incentive (PLI) scheme to manufacture critical molecules like Penicillin G, 6-APA, and Clavulanic Acid, which are essential for antibiotic production. These efforts aim to bolster domestic production and decrease reliance on Chinese imports.

The Ezetimibe export market from India is highly concentrated, with the top five exporters accounting for 91.1% of the market share. PIRAMAL PHARMA LIMITED alone holds a 61.3% share, indicating a significant single-source risk. Such concentration can lead to supply vulnerabilities if any of these key players face operational disruptions.

To mitigate this risk, the Indian government's PLI scheme aims to diversify the supplier base by encouraging new entrants into the API manufacturing sector. By providing financial incentives, the scheme seeks to enhance production capacity and reduce the industry's reliance on a limited number of suppliers.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt supply chains. For example, disruptions in the Red Sea have led to ships rerouting around the Cape of Good Hope, adding over 12 days to shipping times. (gov.uk) Such delays can impact the timely delivery of pharmaceutical products, including Ezetimibe.

Additionally, regulatory bodies like the FDA and EMA have reported medicine shortages due to various factors, including manufacturing issues and increased demand. In November 2024, the EMA launched the European Shortages Monitoring Platform to centralize and automate data collection on medicine supply and demand, aiming to prevent and manage shortages more effectively. (ema.europa.eu)

• Diversify Supplier Base: Encourage the development of additional API manufacturers to reduce reliance on a few key suppliers.

• Enhance Domestic Production: Invest in domestic manufacturing of KSMs and APIs to decrease dependency on imports, particularly from China.

• Strengthen Supply Chain Monitoring: Implement robust systems to monitor supply chain vulnerabilities and respond proactively to potential disruptions.

• Develop Contingency Plans: Establish comprehensive contingency plans to address potential geopolitical and logistical disruptions affecting shipping routes.

• Engage in Regulatory Collaboration: Work closely with international regulatory bodies to stay informed about potential shortages and coordinate responses effectively.

RISK_LEVEL: MEDIUM